Patent intelligence · US
US 12023383
Lipid compositions
Lipid compositions
Patent details — US 12023383
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 2, 2024
- Expiration
- Jun 27, 2044
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Claims
- 20
- CPC classes
- A61K, A61K47/22, A61K9/1272, A61P
Quick answer
US 12023383 (Lipid compositions) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Jul 2, 2024. Expires Jun 27, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K47/22, A61K9/1272, A61P, A61P3/00, A61P31/00
More from ARBUTUS BIOPHARMA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12357705
Negatively charged peg-lipid conjugates
granted -
US 12350383
Cationic lipids containing silicon
granted -
US 12251470
Lipid nanoparticle formulations
granted -
US 12129467
Non-liposomal systems for nucleic acid delivery
granted -
US 12083118
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
granted -
US 12043833
Targeted compositions
granted -
US 12042541
Lipids and compositions for the delivery of therapeutics
granted
Related coverage
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape
In May 2026, the FDA issued 8 oncology and hematology approvals, including durvalumab for high-risk non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and what to watch next in FDA oncology guidance.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approves Durvalumab and BCG for High-Risk NMIBC
The FDA has approved Durvalumab and BCG for patients with high-risk non-muscle invasive bladder cancer (NMIBC). This approval marks a significant development in oncology treatment options.
Frequently asked questions
What is US patent 12023383?
US 12023383 (Lipid compositions) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Jul 2, 2024. Expires Jun 27, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12023383?
ARBUTUS BIOPHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 56 pharmaceutical patents for this assignee.
When does US 12023383 expire?
Our index shows an expiration date of Jun 27, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.